A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Running, not enrolling · Phase 1
Conditions studied: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
In brief
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Key facts
- Study ID
- NCT05784441
- Run by
- Janssen Research & Development, LLC
- People needed
- 21
- Starts
- 2023-11-06
- Expected to finish
- 2040-01-03
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hadassah Medical Center — Jerusalem, Israel
- Sheba Medical Center — Ramat Gan, Israel
- Westmead Hospital — Westmead, Australia
- University of Iowa Hospital — Iowa City, Iowa, United States
- University of Kentucky — Lexington, Kentucky, United States
- Mayo Clinic Rochester — Rochester, Minnesota, United States
- Rutgers University — New Brunswick, New Jersey, United States
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Royal Prince Alfred Hospital — Camperdown, Australia
- Monash Medical Centre — Clayton, Australia
- Austin Hospital — Heidelberg, Australia
- Royal Brisbane and Women's Hospital — Herston, Australia
- University College London Hospitals — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.